Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharma

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

Cigna

DexCom

Elevance Health Inc

Humana

Eli Lilly

UnitedHealth Group

The Baron Health Care Fund's first five years have been exceptional in every sense of the word. Launched in spring 2018, the fund has navigated around the COVID-19 pandemic, a biotech initial public offering market that boomed and fizzled, and D.C.

These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.

Cabaletta Bio

Community Health Systems

Novavax

Organogenesis Holdings

Pfizer

Ultragenyx Pharmaceutical

Viking Therapeutics

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

TipRanks reveals the top 10 health care sector analysts of the past decade

MADISON, Wis. , May 17, 2023 /PRNewswire/ -- Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded $1.1 million to 18 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program.

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

UiPath

Tesla

The Cathie Wood style of investing has certainly fallen out of favor over the last year or two. While some growth stocks have rebounded nicely, many Cathie Wood stocks have been crushed.

3 AI Stocks That Famed Investor Cathie Wood Is Betting On

Exact Sciences (NASDAQ:EXAS) Corporation earned a price target raise from Canaccord Genuity (TSX:CF, LSE:CF) after the molecular diagnostics company specializing in the detection of early-stage cancers reported its first quarter results. The analysts upped their price target from US$75 to US$92 and repeated their ‘Buy' rating on the stock.

Exact Sciences positioned for a solid year after ‘impressive' 1Q, broker says

Diagnostic and cancer test products provider Exact Sciences Corp. NASDAQ: EXAS saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer detection test Cologuard.

Exact Sciences Serves Investors Exactly What They Wished For

Adaptive Biotechnologies

GlaxoSmithKline

Medicine is not always simple. A drug that cures one patient can easily kill another, based on anything from their weight to their genes to anything else.

3 Personalized Medicine Stocks to Buy for Long-Time Returns

Exact Sciences has been hit hard by the challenging economy over the past year or so. Recent strong results have investors thinking the selling has simply gone too far.

A Bull Market Is Coming: 1 Supercharged Growth Stock to Buy Hand Over Fist Before It Soars 164%, According to Wall Street

Exact Sciences reported first-quarter earnings last Tuesday. Thanks to multiple positive developments, investors bid up the biotech's shares this week.

Why Exact Sciences Stock Roared Higher This Week

Several analysts upgraded their price targets for Exact Sciences. The company saw revenue rise by 24% year over year.

Why Shares of Exact Sciences Rose on Wednesday

The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.

Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised

Exact Sciences Corporation (NASDAQ:EXAS ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Megan Jones - IR Kevin Conroy - Chairman & CEO Jeffrey Elliott - CFO & COO Everett Cunningham - Chief Commercial Officer Conference Call Participants Brandon Couillard - Jefferies Catherine Schulte - Baird Vijay Kumar - Evercore ISI Andrew Brackmann - William Blair Jack Meehan - Nephron Research Daniel Arias - Stifel Derik De Bruin - Bank of America Matt Sykes - Goldman Sachs Dan Brennan - Cowen Puneet Souda - SVB Securities Kyle Mikson - Canaccord Genuity Alex Nowak - Craig-Hallum Capital Group Operator Thank you for standing by. My name is Jordan, and I'll be your conference operator today.

Exact Sciences Corporation (EXAS) Q1 2023 Earnings Call Transcript

Exact Sciences (NASDAQ: EXAS ) reported results for the first quarter of 2023. Exact Sciences reported a loss per share of 42 cents.

EXAS Stock Earnings: Exact Sciences Beats EPS, Revenue Estimates

Exact Sciences crushed first-quarter expectations late Tuesday and raised its outlook for the year. The news is likely to stoke EXAS stock.

Exact Sciences Posts Its 11th Consecutive Sales Beat As It Targets 'The Most Preventable' Cancer

Reports record results, raises full-year guidance, accelerates path to positive free cash flow First  quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 million of core revenue, an increase of 33% Full-year 2023 revenue guidance raised by $110 million at the midpoint Expect to turn free cash flow positive during 2023, ahead of previous target of 2024 MADISON, Wis. , May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.

Exact Sciences Announces First Quarter 2023 Results

Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard® is more effective when compared to hypothetical blood-based screening1-3 MADISON, Wis. , May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, presented new data supporting the company's research and innovation in colorectal cancer (CRC) during Digestive Disease Week® (DDW) 2023, May 6-9 in Chicago, Illinois.

Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting

Lithium Americas Corp

Transocean

Finding stocks that will outperform the market is a daunting task in any market. It's challenging when every sector in the S&P 500 is getting hammered.

3 Stocks That AI Predicts Will Outperform the Market

MADISON, Wis. , May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Exact Sciences to participate in May investor conference

Demographic trends are powerful and experience little impact from economic cycles. As the Millennial generation enters middle age and surpasses the number of Baby Boomers, the demand for medical screening and testing will increase.

Exact Sciences: Ready To Benefit From Aging Millennials

BigCommerce Holdings, Inc.

Colgate-Palmolive

Notable companies to have witnessed solid earnings acceleration as of now are ColgatePalmolive (CL), BigCommerce (BIGC) & Exact Sciences (EXAS).

3 Top Earnings Acceleration Stocks Worth Buying

Avalo Therapeutics

Oric Pharmaceuticals

Twist Bioscience Corp

INmune Bio Inc

Synlogic

Tenaya Therapeutic

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

The 7 Best Biotech Stocks for Personalized Medicine Investors

Unity Software

Cathie Wood is a well-known though polarizing investor. As the founder and CEO of the investment management firm ARK Invest, she has an investment philosophy that focuses on innovative technologies and growth stocks.

Cathie Wood's Next Big Bet: 3 Disruptive Innovations to Watch

Coinbase

Catherine Wood (Trades, Portfolio) disclosed her firm's first-quarter 2023 portfolio last week.

Cathie Wood Boosts Coinbase, Tesla Holdings, Cuts Back Exact Sciences

News for Exact Sciences Stock (EXAS)